Kevin Lin

Head of Translational Medicine

Revolution Medicines

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kevin Lin is the Head of Translational Medicine at Revolution Medicines in the United States. His research focuses on the application of rucaparib in various contexts, including its use as maintenance treatment in ovarian cancer and the evaluation of its effectiveness in patients with genetic variants associated with homologous recombination repair. Dr. Lin has contributed to significant studies, including LODESTAR and ATHENA, aimed at improving therapeutic approaches in oncology.

Articles (10)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Matthew Wakefield

University of Melbourne

AUSTRALIA

View details

Iain McNeish

Imperial College London

UNITED KINGDOM

View details

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

View details

Robert L. Coleman

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin Lin

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes

Reply to C. Marchetti et al

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

Collaborators (4)

Matthew Wakefield

Iain McNeish

Rebecca S. Kristeleit

Robert L. Coleman

Make your next move.